This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Regeneron (REGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teva's (TEVA) Q3 Earnings and Revenues Miss, Stock Down
by Zacks Equity Research
Teva Pharmaceutical Industries' (TEVA) shares decline after the company misses both earnings and sales estimates for third-quarter 2021. Meanwhile, it reaffirms its 2021 guidance.
Sanofi (SNY) Q3 Earnings Beat, Sales Miss, 2021 EPS View Up
by Zacks Equity Research
Sanofi (SNY) beats third-quarter estimates for earnings but misses the same for sales. It raises earnings growth guidance range for the year.
Will Higher Jakafi Sales Boost Incyte's (INCY) Q3 Earnings?
by Zacks Equity Research
Incyte's (INCY) third-quarter 2021 earnings are likely to have gained from higher Jakafi sales as patients resume visits to the doctors.
Top 5 High ROE Stocks to Buy as Fed Tapering Looms Large
by Supriyo Bose
Seagate Technology (STX), Best Buy (BBY), Celanese Corporation (CE), CBRE Group (CBRE), and Regeneron Pharmaceuticals (REGN) are some stocks with high ROE to buy as the Fed tapering decision is expected soon.
Regeneron (REGN) Stock Moves -0.43%: What You Should Know
by Zacks Equity Research
Regeneron (REGN) closed at $589.60 in the latest trading session, marking a -0.43% move from the prior day.
Biotech Stock Roundup: BMY's Q3 Earnings Beat, MRNA's Vaccine Updates & More
by Zacks Equity Research
Earnings and other updates from bigwigs like Bristol Myers (BMY) and Moderna (MRNA) have been the biotech sector's few key highlights during the past week.
Vertex (VRTX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On Vertex Pharmaceuticals' (VRTX) third-quarter earnings call, investors are most likely to focus on the sales performance of its triple combo CF drug Trikafta/Kaftrio and pipeline progress.
Bristol-Myers (BMY) Beats on Q3 Earnings & Sales, Tweaks View
by Zacks Equity Research
Bristol-Myers (BMY) beats on earnings and sales in the third quarter on the back of Revlimid, Eliquis, and Opdivo.
Repligen (RGEN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On Repligen's (RGEN) third-quarter earnings call, investor focus is likely to be on the sales performance of its product franchisees - filtration, chromatography, protein and process analytics.
Eli Lilly (LLY) Q3 Earnings Miss, COVID Drugs Drive Sales
by Zacks Equity Research
Eli Lilly (LLY) reports mixed third-quarter results and raises its 2021 sales forecast.
Novartis (NVS) Q3 Earnings Beat, Sandoz Under Strategic Review
by Zacks Equity Research
Novartis (NVS) reports mixed results in the third quarter, as key brands maintain momentum but generics business remains weak.
CRISPR (CRSP) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On CRISPR Therapeutics' (CRSP) Q3 earnings call, investor focus will likely be on updates on the company's pipeline candidates, especially its lead candidate CTX001.
Gilead (GILD) to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) third-quarter 2021 results.
The Zacks Analyst Blog Highlights: Goldman Sachs, Chevron, ConocoPhillips, Regeneron Pharmaceuticals and Exxon Mobil
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Goldman Sachs, Chevron, ConocoPhillips, Regeneron Pharmaceuticals and Exxon Mobil
Regeneron (REGN) Dupixent Meets Goal in Prurigo Nodularis Study
by Zacks Equity Research
Regeneron's (REGN) phase III study on Dupixent for treating adults with uncontrolled prurigo nodularis meets its primary and all secondary endpoints.
LabCorp (LH) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
LabCorp's (LH) Covance Drug Development third-quarter results are expected to reflect an increase in organic revenues in the base business.
Intellia's (NTLA) CRISPR Therapy Gets FDA's Orphan Drug Tag
by Zacks Equity Research
Intellia's (NTLA) investigational gene-editing therapy, NTLA-2001, gets Orphan Drug tag from the FDA for ATTR amyloidosis.
What is in Store for Bristol-Myers (BMY) in Q3 Earnings?
by Zacks Equity Research
Bristol-Myers' (BMY) Q3 earnings might have gained from strong demand for its multiple myeloma drug, Revlimid. Operating expenses might have jumped due to costs associated with the broader portfolio.
Major Stock Indexes Hit Record-High Level: 5 Top-Ranked Picks
by Nalak Das
We have narrowed down our search to five stocks that are members of any of the three major stock indexes. These are: GS, XOM, CVX, COP and REGN.
Regeneron (REGN) Dupixent Gets FDA Nod for Asthma in Children
by Zacks Equity Research
Regeneron (REGN) and Sanofi's (SNY) Dupixent secures FDA approval to treat children aged 6-11 years with moderate to severe asthma.
Boston Scientific (BSX) Product Launches to Drive Q3 Earnings
by Zacks Equity Research
Within Urology/ Pelvic Health, Boston Scientific (BSX) is expected to have registered strong sales growth in Stone, Prostate Health and Pelvic Health franchises.
Radius (RDUS) Up On Positive Data From Breast Cancer Study
by Zacks Equity Research
Radius (RDUS) stock gains in response to positive results from a late-stage study evaluating breast cancer candidate, elacestrant.
Will Eli Lilly (LLY) Surpass Q3 Earnings Expectations?
by Zacks Equity Research
Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) third-quarter sales.
Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Regeneron (REGN) closed at $562.71, marking a +1.92% move from the previous day.